Valuation: Design Therapeutics, Inc.

Market Cap 785M 688M 636M 585M 1.1B 75.71B 1.12B 7.61B 2.98B 37.04B 2.95B 2.88B 128B P/E 2026 *
-9.27x
P/E 2027 * -7.66x
Enterprise Value 605M 530M 490M 451M 850M 58.33B 864M 5.86B 2.3B 28.54B 2.27B 2.22B 98.33B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day-3.78%
1 week-12.96%
Current month-16.66%
1 month-11.97%
3 months-8.36%
6 months+27.62%
Current year+28.57%
1 week 12.03
Extreme 12.03
14.83
1 month 12.03
Extreme 12.03
15.86
Current year 8.23
Extreme 8.23
17.25
1 year 3.76
Extreme 3.76
17.25
3 years 1.94
Extreme 1.94
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 2023-08-24
Chief Tech/Sci/R&D Officer - 2021-05-31
Chief Operating Officer 46 2020-12-31
Director TitleAgeSince
Chairman 56 2017-12-17
Director/Board Member 71 2019-06-30
Director/Board Member 49 2020-01-31
Date Insider Type Main position Quantity % Market Cap.
6/9/26 Free

Director

30,000 0.0480%
6/9/26 Free

Director

30,000 0.0480%
6/9/26 Free

Director

30,000 0.0480%
Change 5-day change 1-year change 3-year change Capi.($)
-3.42%-12.96%+197.78%+68.91% 785M
-0.49%-4.01%+0.61%+2.28% 49.18B
-1.97%-0.13%+378.16%+584.97% 39.58B
-0.86%+2.77%+7.01%+61.95% 34.69B
-0.71%-0.97%+29.30%-9.20% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-2.81%-4.12% - - 16.21B
-1.05%+0.74%+72.92%+116.33% 15.36B
+1.17%+2.30%+15.46%+18.26% 14.05B
-2.59%+0.28%+19.29%-32.68% 13.02B
Average -1.13%-1.88%+80.12%+93.65% 24.44B
Weighted average by Cap. -0.76%-0.43%+78.90%+121.10%

Financials

2026 *2027 *
Net sales - -
Net income -85.49M -74.93M -69.26M -63.7M -120M -8.24B -122M -828M -325M -4.03B -321M -314M -13.9B -116M -102M -94.08M -86.52M -163M -11.2B -166M -1.12B -441M -5.48B -436M -427M -18.88B
Net Debt -180M -158M -146M -134M -253M -17.38B -257M -1.75B -684M -8.5B -677M -662M -29.29B -106M -93M -85.96M -79.06M -149M -10.23B -152M -1.03B -403M -5.01B -398M -390M -17.25B
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
54
Date Price Change Volume
26-07-20 US$12.22 -2.78% 201,732
26-07-17 US$12.57 -0.32% 468,167
26-07-16 US$12.61 -6.73% 900,806
26-07-15 US$13.52 -1.10% 396,307
26-07-14 US$13.67 -1.34% 582,411
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
12.57USD
Average target price
21.00USD
Spread / Average Target
+67.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSGN Stock